NHS Halts Hormone Treatment for Questioning Teens Amid Evidence Concerns

NHS England has declared a pause on new dispensing of cross-sex hormones for 16 and 17-year-olds exploring gender identity questions, in the wake of a thorough examination that determined earlier studies into the drugs’ safety and effectiveness was inadequate. The decision, which takes effect immediately, comes after an impartial assessment of evidence commissioned by the health service determined there was inadequate quality evidence to determine whether the hormones benefit or harm teenagers. Teenagers currently on the treatment will keep taking their medication, though clinicians will be asked to review their cases. NHS England said a limited number of teenagers would be affected by the pause and will be provided with other treatment options at three gender clinics operated by the NHS for children operating across England.

The Decision and Its Scope

The pause reflects a major change in NHS England’s strategy for gender-affirming medical care for teenagers. Cross-sex hormones, which assist those acquire physical characteristics associated with their preferred gender, can result in permanent alterations including a lower voice, breast growth, or other lasting changes. The decision to stop new prescriptions comes from the NHS’s assessment that existing evidence cannot clearly demonstrate whether these interventions assist or injure teenagers dealing with gender dysphoria. Professor James Palmer, National Medical Director for Specialised Services at NHS England, emphasized that the review had been “exceptionally thorough and complex,” ultimately determining that available evidence does not support continued prescription of masculinising or feminising hormone treatments for under-18s.

NHS England has started a 90-day public consultation commencing Monday to collect additional feedback on the updated policy and review findings. The NHS hopes this consultation period will identify any evidence that may have been overlooked during the initial review process. Existing guidance already banned prescriptions for under-16s requesting gender-related treatment, so the new pause essentially broadens restrictions to cover 16 and 17-year-olds. The NHS stressed its dedication to offering full support, stating that young people who cannot receive hormone therapy will be provided with alternative care options through its three specialized gender clinics for children across England.

• Pause covers new prescriptions for 16 and 17-year-olds only
• Young people already on hormones will proceed with ongoing treatment
• Clinicians will review current cases for ongoing suitability
• Alternative care available at three NHS gender clinics nationally

Review of Evidence Findings

The choice to pause hormone prescriptions stems directly from a thorough evidence assessment commissioned by NHS England, which assessed the scientific basis for cross-sex hormone treatment in adolescents. The review, comprising ten independent assessments of various dimensions of testosterone and oestrogen use, uncovered notable deficiencies in the research underpinning existing clinical practice. NHS England concluded that the available evidence was inadequate to establish whether these therapies benefit or harm young people with gender dysphoria, making it impossible to justify continuing new prescriptions with confidence in their safety and effectiveness.

This conclusion reflects worries expressed in Dr Hilary Cass’s substantial April 2024 assessment on pediatric gender care, which noted “extremely limited” evidence regarding clinical treatments in this domain. The Cass review encouraged NHS England to undertake its own thorough analysis of the scientific evidence. The resulting review focused on multiple outcomes for young patients, such as quality of life, emotional health, and overall wellbeing. Rather than waiting for further evidence to emerge, NHS England decided to adopt a precautionary approach, pausing fresh prescriptions while continuing to evaluate input from advocacy groups and clinical staff.

Study Results

The ten independent evidence assessments examined the effects of masculinising and feminising hormones across a range of health and psychological outcomes for adolescents with a gender identity different from their sex at birth. Researchers assessed published studies on how these treatments affected life quality, mental health status, and distress related to gender identity in young people. The review was intentionally thorough, seeking to examine all available evidence in assessing whether sufficient evidence existed to justify continued prescribing practices for individuals under 18 years old.

The overarching conclusion was clear: the body of evidence did not reach the threshold needed to with certainty recommend hormone treatment for this demographic. Professor Palmer noted that the review “established that the body of evidence does not justify the sustained use of hormone treatments” to treat young people under 18 with gender-related conditions. This conclusion meant NHS England was unable to determine whether the treatments were harmful or effective, calling for a suspension subject to additional evidence and clinical guidance.

• Ten distinct analyses analyzed various dimensions of endocrine treatment
• Research evaluated life quality and mental health outcomes
• Body of evidence deemed insufficient to warrant ongoing treatment
• Insufficient data to show if therapies negatively affect or help young people

Public Response and Legal Battles

The NHS choice to suspend hormone prescriptions has prompted swift and polarised responses from across the healthcare and advocacy sectors. Trans advocacy groups have voiced firm objection to the policy change, with some organisations indicating their plans to take legal proceedings against NHS England. These groups contend that the pause restricts access to transformative treatment for adolescents experiencing gender dysphoria, and contend that the evidence review does not justify such a limiting stance. The consultation phase beginning Monday will be vital in establishing whether NHS England’s stance shifts or strengthens based on stakeholder feedback.

Healthcare practitioners working in gender identity programs have also commented on the decision, with views extending across cautious support to significant concern. Some clinicians endorse the evidence evaluation as a required action to confirm treatments are sufficiently evidence-based, while others express concern that the pause may damage vulnerable young people who have commenced hormone therapy or are seeking to obtain care. The 90-day consultation period constitutes an opportunity for these varied perspectives to put forward their perspectives, potentially influencing whether the temporary pause turns into permanent policy or is revised based on emerging research or professional consensus.

Advocacy Group Statement

Trans advocacy bodies have objected to the NHS pause as discriminatory and potentially damaging to young people in vulnerable situations. These groups argue that the decision to halt additional prescriptions runs counter to the testimonies of transgender youth who cite better psychological outcomes and quality of life after hormone therapy. They assert that the review’s findings of “weak evidence” cannot support such a limiting approach, and that the pause effectively denies care to individuals requiring it most while pending complete scientific confirmation that might never emerge.

Legal challenges are expected, with activist groups stating they intend to pursue legal proceedings to overturn or modify the treatment suspension. These organisations argue that the decision violates the rights of youth to access appropriate medical care and might represent prejudice toward gender expression. They highlight that case-by-case evaluations ought to decide treatment eligibility as opposed to universal prohibitions, and that the consultation process should carefully examine testimony from transgender communities themselves about lived experiences with hormone-based treatment.

Commercial Sector and International Context

While NHS England implements its measured approach, the private medical industry in the UK continues to offer hormone treatments to young people outside the state healthcare provision. This results in a stratified healthcare model where wealthier families may access treatments that the NHS has suspended, generating questions about fairness and availability. The gap between NHS policy and private provision draws attention to broader questions about how evidence-based guidelines should work across various healthcare environments, and whether teenagers’ ability to access to gender-affirming medical care should depend on their family’s economic circumstances rather than clinical requirement.

Internationally, healthcare systems have adopted different strategies to hormone treatment for young people questioning their gender. Some European countries, including Sweden and Finland, have likewise restricted restrictions on gender-affirming hormones for minors in recent years, pointing to a lack of evidence. Conversely, other nations maintain more permissive treatment guidelines, with some medical organisations arguing that withholding care results in greater psychological harm. These divergent international responses underscore the genuine scientific uncertainty regarding the long-term effects and benefits of these interventions, and suggest that no consensus yet exists among global medical authorities on the appropriate treatment pathway for adolescents with gender dysphoria.

• Private clinics in the UK continue to offer hormonal therapy to minors in spite of NHS pause
• Sweden and Finland have equally curbed hormone prescriptions for young people in the past few years
• International health bodies continue to disagree on appropriate treatment protocols for young people

What Comes Next

NHS England has launched a formal framework to decide on its long-range strategy on hormone treatment for adolescents exploring their gender identity. A three-month public engagement commenced on Monday will gather feedback from advocacy groups, medical practitioners, and the broader community on the evidence review findings and updated recommendations. The health service has stressed that this consultation period is essential for identifying any information missed during initial review during the first review stage. The outcomes will determine whether the present suspension on fresh prescriptions becomes enduring practice or whether treatment restarts under revised parameters.

During the assessment window, NHS England will keep monitoring and supporting young people presently on hormone treatment, with clinicians performing individual assessments of each patient’s care plan. The three existing NHS gender clinics for children will broaden their scope of alternative care options for those unable to access hormones, including mental health support and counselling. Upon completion of the 90-day period, NHS England will analyse all feedback received and reach a final determination regarding long-term policy. This decision will have major consequences for many young people across England seeking gender-affirming medical interventions.

The 90-Day Consultation Procedure

The consultation represents a formal opportunity for stakeholders to support or challenge NHS England’s initial conclusions. Campaign organisations, medical professionals, and members of the general public can provide evidence and viewpoints on whether the review correctly represents current scientific understanding. Trans advocacy organisations have already indicated they may take legal action, indicating the consultation will be disputed. NHS England has indicated it will carefully review all responses, specifically aiming to find any high-quality evidence that the initial review may have missed or underweighted in its analysis.

The 90-day period is designed to balance the requirement for thorough consideration with the urgency of offering clear guidance to youth and healthcare providers presently unclear about available treatments. NHS England will gather and review all consultation responses before issuing its definitive ruling on new guidance. This extended period permits healthcare professionals to share practical experience, research organizations to submit further data, and youth in their own right to explain how the revised policies affect their wellbeing and quality of life.